Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • FTC seeks to block...

    FTC seeks to block Illumina from buying PacBio

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-12-20T09:00:02+05:30  |  Updated On 20 Dec 2019 9:00 AM IST

    The Federal Trade Commission said in a statement that it filed the antitrust complaint because of concern that Illumina wanted the deal in order to prevent PacBio from developing into a competitor in the market for next-generation DNA sequencing.


    New Delhi: The Federal Trade Commission has filed a complaint aimed at stopping Illumina Inc from purchasing Pacific Biosciences of California, the agency said on Tuesday.


    Shares of PacBio fell about 7.5 percent in after-hours trading.


    The agency said in a statement that it filed the antitrust complaint because of concern that Illumina wanted the deal in order to prevent PacBio from developing into a competitor in the market for next-generation DNA sequencing.


    The deal was valued at $1.2 billion when it was announced in November 2018.


    Illumina said in a statement that it would push for the transaction to close. "We strongly disagree with the FTC's decision and will continue to work through the regulatory approval process as we consider next steps," the company said in a statement.


    The FTC said it also authorized the filing of federal court actions to request a temporary restraining order and a preliminary injunction if needed to prevent the companies from closing the deal.


    Gene sequencing is a method to analyze the genome, and among other uses, can help identify inherited disorders and markers of disease progression.


    The commission, which is comprised of three Republicans and two Democrats, voted 5-0 to file a complaint with an FTC administrative law judge to argue that Illumina's purchase of PacBio, an up-and-coming rival, is an effort to unlawfully maintain its DNA sequencing systems monopoly.


    "When a monopolist buys a potential rival, it can harm competition," said Gail Levine, deputy director of the FTC Bureau of Competition. "These deals help monopolists maintain power. That's why we're challenging this acquisition."


    Read Also: CMA refers Illumina-Pacific Biosciences deal for in-depth investigation


    The FTC said PacBio had made advances in recent years that made its analyses more accurate and less expensive.


    "Customers have already switched some sequencing volume from Illumina to PacBio for certain use cases and applications, and PacBio is poised to take increasing sequencing volume from Illumina in the future," the FTC said in a statement.


    Read Also: Bristol Myers Squibb gets FTC okay for acquiring Celgene

    DNA sequencingFederal Trade CommissionIlluminaIllumina IncInherited disorderspacbioPacific Biosciencespharmapharma companypharma news
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok